Copyright
©The Author(s) 2020.
World J Gastroenterol. Apr 14, 2020; 26(14): 1580-1593
Published online Apr 14, 2020. doi: 10.3748/wjg.v26.i14.1580
Published online Apr 14, 2020. doi: 10.3748/wjg.v26.i14.1580
Target | Drug | Commercial name | Indication |
PD-1 | Nivolumab | Opdivo | Hepatocellular carcinoma, colorectal cancer with MSI-H |
PD-1 | Pembrolizumab | Keytruda | Gastric cancer, hepatocellular carcinoma, colorectal cancer, solid tumors with MSI-H |
CTLA-4 and PD-1 | Ipilimumab plus nivolumab | Yervoy plus Opdivo | Colorectal cancer with MSI-H |
- Citation: Chivu-Economescu M, Necula LG, Matei L, Dragu DL, Neagu AI, Alexiu I, Bleotu C, Diaconu CC. Gastrointestinal cancer stem cells as targets for innovative immunotherapy. World J Gastroenterol 2020; 26(14): 1580-1593
- URL: https://www.wjgnet.com/1007-9327/full/v26/i14/1580.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i14.1580